439 related articles for article (PubMed ID: 25220043)
1. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
[TBL] [Abstract][Full Text] [Related]
2. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
3. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
Berland DW; Malinoff HL; Weiner MA; Przybylski R
Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
[TBL] [Abstract][Full Text] [Related]
4. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
7. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans.
Kornfeld H; Reetz H
Am J Ther; 2015; 22(3):199-205. PubMed ID: 23846520
[TBL] [Abstract][Full Text] [Related]
8. Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series.
Martin YN; Deljou A; Weingarten TN; Schroeder DR; Sprung J
BMC Anesthesiol; 2019 May; 19(1):68. PubMed ID: 31068127
[TBL] [Abstract][Full Text] [Related]
9. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
Uberall MA; Müller-Schwefe GH
Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
[TBL] [Abstract][Full Text] [Related]
10. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
[TBL] [Abstract][Full Text] [Related]
11. Conversion of Schedule II Opioids to Buprenorphine Buccal Film: A Retrospective Analysis.
Zimmerman A; Bikdash R; Rauck R
Pain Med; 2021 May; 22(5):1109-1115. PubMed ID: 32914182
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
14. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
Lim SCB; Schug S; Krishnarajah J
Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
[TBL] [Abstract][Full Text] [Related]
15. Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy.
Mehta D; Thomas V; Johnson J; Scott B; Cortina S; Berger L
Pain Physician; 2020 Mar; 23(2):E163-E174. PubMed ID: 32214293
[TBL] [Abstract][Full Text] [Related]
16. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine for chronic pain.
Calderon R; Copenhaver D
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
[TBL] [Abstract][Full Text] [Related]
20. Sublingual buprenorphine for chronic pain: a survey of clinician prescribing practices.
Rosen K; Gutierrez A; Haller D; Potter JS
Clin J Pain; 2014 Apr; 30(4):295-300. PubMed ID: 23727654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
